Background: Hyperlipidemia is a major cause of atherosclerosis-induced conditions such as coronary heart disease, ischemic cerebrovascular disease, and peripheral vascular disease. Due to various adverse effects with the current pharmacological therapy, many plant-derived compounds are being tested to lower serum lipid levels. Genistein, a soy isoflavone, showed promising results in several studies.
Aims and Objectives: The study aimed to evaluate the effectiveness of genistein on serum lipid profile and its hepatoprotective activity in hyperlipidemic male albino Wistar rats.
Materials and Methods: Thirty-six male Wistar rats were randomly divided into six groups. Animals were given high cholesterol diet (0.75% cholesterol + 1.5% bile salt) to induce hyperlipidemia. The animals were treated with atorvastatin (10 mg/kg oral) and genistein (1 mg/kg oral and 5 mg/kg oral) once daily for a period of 30 days. Blood samples were collected for biochemical analysis of lipoproteins and a portion of liver tissue was taken for histopathological examination. Statistical analysis was performed by one-way analysis of variance test followed by post hoc Dunnetts multiple comparison test. P < 0.05 was considered statistically significant.
Results: Oral administration of genistein showed a significant reduction in serum total cholesterol, triglycerides, and low-density lipoprotein levels. Histopathological examination of liver showed a significant reduction in hepatic steatosis (P < 0.001) with no inflammatory changes as compared to high cholesterol-treated rats.
Conclusion: The present study demonstrated significant hypolipidemic and hepatoprotective activities of genistein at a dose of 5 mg/kg in the experimental rats.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
